SIRT1 and metabolic syndrome: The enlightening findings suggest that Doxercalciferol and Timiperone can be effective molecules for developing potential SIRT1 inhibitors, offering possibilities for addressing various complex diseases like cancer, neurodegenerative disorders, and metabolic syndromes.